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Abstract: Nonpalpable breast lesions are being detected with the advent of improved
mammographic techniques. Although only
20-30 % of these lesions are malignant, definitive diagnosis has usually required a needle-localization breast biopsy during a 6 year
period were reviewed to determine the effect
of this procedure on the diagnosis and treatment of early breast cancer. Calcifications
were the most common mammographic abnormality for biopsy. Of the 62(27%) patients diagnosed with malignancy, 38 (61%)
had invasive carcinoma and 24 (39%) had
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Introduction
Worldwide, breast cancer is the leading cause of
cancer death in women. It is estimated that by the
year 2000, one million women a year will receive a
diagnosis of breast cancer. When breast cancer is diagnosed before it becomes palpable, its mortality can
be reduced, even for women in their 40s (1, 2). The
frequent use of screening mamography in women has
resulted in a large number of biopsies being performed for nonpalpable breast lesions. The lesion is by
definition clinically not apparent, and surgical excision
is further complicated by the plastic nature of the
breast. Blind segmentectomy or quandrantectomy were
the initial techniques used for obtaining tissue diagnosis of radiographic lesions, but high rates of reexcision for persistent lesions were reported. Attempts
at external referencing with an applied grid or radiographically placed skin marker failed to improve the
results of surgical biopsy and were time-consuming.
Needle localization breast biopsy (NLBB) has significantly increased the first excision recovery rate of
breast biopsy for nonpalpable lesions.
To remove lesions using NLBB requires that the
surgeon follow a needle placed mammographicaly either into or in close proximity to the area of suspicion. Needle localization biopsy of nonpalpable masses or microcalcifications leads to the diagnosis of
malignancy in 9% to 38% of biopsies (1-7).

noninvasive carcinoma. Breast conservation
was the most common form (53%) of surgical treatment in this study. Metastatic disease involving the axillary Iymph nodes was
found in 23% of our patients who underwent axillary dissection. We conclude that
needle localized breast biopsy continues to be
a reliable method of detecting early breast
carcinoma. Given the minimal morbidity, this
procedure sould be done in all patients with
mammographically suspicious nonpalpable
breast lesions.

The appearance of the lesion on mammography is
the most important factor deciding whether a biopsy
should be performed. Another factor for nonpalpable
breast lesions is the age of the patient. The rate of
carcinoma after needle localization breast biopsy is
37% in women 50 years of age or older and 17% in
women less than 50 years of age. Personal or family
history of breast cancer and whether the lesion had
changed during observation are other factors for
breast biopsy with needle localization (3).
It is the purpose of this paper to evaluate a series
of nonpalpable breast cancers diagnosed at Department
of General Surgery, Ege University School of Medicine,
from 1989 to 1995.
Materials and methods
During a 6-year period, 230 patients underwent biopsy after needle localization of nonpalpable breast lesions at Ege University Medical School. Data analyzed
included the histologic diagnosis, patient age, personal
or family history of breast cancer, type of surgical
procedure performed, and axillary lymph node status.
The patients ranged in age from 30 to 72 years, with
a mean age of 48 years. None of the lesions were
palpable preoperatively. The predominant mammographic finding leading to biopsy described as a
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mass or asymmetric density, suspicious calcifications,
or both.
Fine needle aspiration biopsy and stereotactic core
needle biopsy were not used to evaluate these nonpalpable lesions during the period studied.
Needle localization was performed using a hookwire technique (Homer Mammalok needles) in the radiology department. The patient was then taken to the
operating suite. All biopsies were performed using an
open technique under general anesthesia. Confirmation
of successful biopsy was obtained by immediate specimen mammography while the patient was still in the
operating room. When specimen x-ray indicated that
the lesion was not within the specimen, we did not
perform an immediate reexcision of additional breast
tissue. This approach can lead to unnecessary tissue
loss with resultant breast deformity. Patients with
negative specimen radiographs underwent repeat needle localization biopsy approximately 2 weeks after
first biopsy if the suspicious lesion was present on
postbiopsy mammogram. This time interval allows for
compression of the breast during mammography.
All breast specimens were examined histopathologically, and patients with breast cancer underwent additional procedure, including modified radical mastectomy, wide excision alone or wide excision and
axillary lymph node dissection (level I/II). Adjuvant
therapy was recommended for all patients with involved axillary lymph nodes.
Follow-up is expressed in months from initial diagnosis to date of last known contact. Student’s t-test
was used for statistical analysis of data. Statistical significance was defined at P < 0.05.
Results
A total of 230 mammographic abnormalities were
excised in patients. The lesions consisted of suspicious
calcifications in 120, a mass in 89, and an asymmetric
density in 21cases. Calcifications were the most common indication for biopsy. Most of the lesions (71%)
were located in the upper outer quadrant of the
breast, and biopsies from this region had the highest
incidence of malignancy 40/62 (65%).
Malignant disease was present in 62 of 230 (27%)
nonpalpable lesions. Of the 62 patients diagnosed with
malignancy, 38 (61%) had invasive carcinoma and 24
(39%) had noninvasive carcinoma (ductal carsinoma in
situ, n: 23; lobular carsinoma in situ, n:1). Table I
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summarizes the pathologic diagnosis by types of carcinoma. In biopsy specimens that revealed malignancy,
suspicious calcifications were present 38% of patients.
Tumor size of the 38 invasive carcinomas detected by
NLBB was less than 2 cm (mean 1.4cm) in 18 (47%),
2 to 5 cm (mean 2.7cm) in 20 (53%) patients. The
large nonpalpable tumors, while rare, occured more
commonly as infiltrating lobular histology or as part of
an invasive carsinoma with varying degrees of multifocal invasive components.
Benign lesion was diagnosed in 168 (73%) of the
230 NLBB specimens on pathologic examination. Table
2 summarizes the pathologic results of patients with
benign breast lesion. In this series, only one patient
required more than one biopsy to remove the abnormal mammary tissue, and there were no complications with this technique.
One hundred and thirty-one (57%) of the 230
NLBB were performed in patients under age 50. Malignancy was present in 25 of (19%) patients. In
women over age 50, 37 (37%) of 99 NLBB performed were malignant . Only six biopsies were malignant in women less than age 40. Malignancy was
significantly more likely in patients 50 years of age or
older (p < 0.01).
Twenty-one patients (9%) had family history of
breast cancer; in 12 (57%) of these patients the biopsy revealed carcinoma. Patients with personal history
of breast cancer was five (2%) of 230 NLBB. In none
of these patients the biopsy revealed cancer.
Breast conservation was the most common form
(53%, n: 33) of surgical treatment in this study.
Modified radical mastectomy was performed in 29 of
the 62 patients with breast cancer. The remaining patients were treated wide excision alone (in 22 patients) or wide excision and axillary lymph node dissection (in 11 patients). We did not performed axillary
dissection for patients with DCIS ( for lesions less
than 25 mm, with histologically clear margins and no
residual calcification of follow-up mammogram) except
one patient (with comedocarsinoma). Patients who are
found to be non-comedo, with low nuclear grade, can
probably be treated by wide local excision alone. All
patients treated by wide excision received breast irradiation in the post-operative period. Patients with
histologically negative axillary nodes did not receive irradiation to nodal areas.
Axillary dissections were performed for 40 of 62
patients with malignancy. Lymph node involvement
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was present in only 9 (23%) of the patients who underwent axillary dissection. Lymph node metastasis
was found in 2 (11%) of the 18 patients with tumors
≤ 2cm. Adjuvant chemotherapy was recommended for
all patients with involved axillary lymph nodes.
The follow-up period ranged from 6 to 84 months
(median, 27 months). Local recurrence and distant
metastasis were not observed during this period.
Table 1.

Pathologic Results of 62 Patients With Carcinoma

Pathology

N

Invasive ductal carcinoma

33

Invasive lobular carcinoma

3

Combined invasive ductal and lobular carcinoma

2

Ductal carcinoma in-situ

23

Lobular carcinoma in-situ

1

Total

Table 2.

Pathologic results of 168 patients with benign breast lesion.

Pathology

N

Fibrocystic change

88

Fibroadenoma

60

Fat necrosis

6

Mild epithelial hyperplasia of usual type

6

Papilloma

4

Total

Of our nonpalpable cancers, 38 (61%) were invasive, and 24 (39%) were noninvasive. These results
correlate with the other large series. Schwartz et al
reported 951 (31%) of 3042 biopsies as malignant,
and 418 (44%) of 951 were noninvasive cancers(10).
Silverstein et al found 395 cancers (22%) in biopsies
performed on 1805 patients, with higher percentage
of noninvasive cancers, 202 (51%) of 395 patients
(11).
Large series report an overall incidence of axillary
metastasis of 40% for women with breast cancer.
Metastatic disease involving the axillary nodes was
found in 23% of our patients who underwent axillary
dissection. This, too, is comparable to others, who
have reported lymph node positivity ranging from 7%
to 25%. (6, 7, 12, 13). Clearly, waiting until these
nonpalpable cancers would become palpable for detection would lead to higher rates of positive axillary
nodes and lower survival rates (5).

62

Duct estasia

who have reported positive rates of 6% to 31% with
NLBB (5, 6).

4
168

Discussion
Breast cancer is one of the most common cancers
diagnosed in Turkey among women. With no current
method of prevention available, early detection of
breast cancer by regular self and physician performed
breast examination in conjunction with screening mammography is emphasized. The rate of breast cancer
detection has accelerated due to the ability of mammography to identify nonpalpable breast lesions. Although only 20-30% of these lesions were malignant,
definitive diagnosis has usually required a NLBB. NLBB
is now a commonly performed procedure in the diagnosis of early breast cancer (8, 9).
In this study, 27% of our NLBB showed malignant
disease. This is consistent with the findings of others,

The reason of mammographic lesions found in the
upper outer quadrant of the breast in this and other
studies is the large volume of breast tissue found in
this quadrant (3, 14). This interpretation was supported by similar biopsy yield rate in the different areas of the breast (8).
The technique of NLBB differs significantly from
excisional biopsy of a palpable breast mass. To prevent
missed lesions in NLBB, the surgeon should follow a
needle “ placed mammographically either into or in
close proximity ” to the area of suspicion. When a
mass is palpable in the breast, the surgeon can more
accurately identify the extent of the lesion for complete excision (6). NLBB can be performed using an
open technique under general anesthesia with less than
a 2 percent chance of missed lesions similar to those
associated with biopsies of palpable lesions. The rate
of missed biopsy in this study was zero and only one
lesion required more than one excision to remove the
abnormal mammary tissue (15).
An abnormal mammogram requiring NLBB in women over age 50, there is 35% risk of malignancy. In
this study, the rate of carcinoma was 37% in women
over age 50. Only, 19% (12 patients) of our NLBB
were malignant in women under age 50. Malignancy
was significantly more likely in patients over age 50
(p < 0.01). Lower biopsy yield rate in young patients
may also be explained by a tendency to recommend
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biopsy more liberally in younger patients because early
diagnosis and treatment may be even more important
in this age group; cancers are usually considered to
progress more rapidly in young patients who have a
greater natural life expectancy. Our results correlate
with the other trials (3, 5, 16).
The risk of carcinoma is increased in patients with
abnormal mammogram and personal or family history
of breast cancer. Several authors reported similar results in patients with personal or family history of
breast cancer. Nine percent (n: 21) of our patients
had family history of breast cancer, in 57% (n: 12) of
these patients the biopsy revealed carcinoma. (3, 17,
18).
Most of the women (53%, n: 33) in this series
were treated with breast-conserving surgery. Level I/II
axillary dissections were performed in 11 of the 38
patients with invasive carcinoma. The remaining patients (n: 22) were treated with wide excision alone,
because these patients had ductal carsinoma in situ.
There is definitively no role for an axillary lymph node
dissection in the management of DCIS. This was concluded in a study by Silverstein which showed less
than 1% involvement of the axillary nodes in cases of
DCIS (19). Of the 29 patients (47%) treated with
modified radical mastectomy, 27 had invasive carcinoma and only 2 had noninvasive carcinoma (Both of
them refused our recommendations about treatment).
In this study, the incidence of modified radical mastectomy is similar to other reported series (4, 18-22).
All patients treated with breast conserving surgery re-

ceived breast irradiation in the post-operative period.
We endorse performing axillary lymph node dissection
only in nonpalpable invasive breast cancer.
Silverstein et al reported a significantly improved
disease-free survival at 7 years for patients with nonpalpable malignancies compared with those who presented with a palpable mass. Wilhelm et al noted a
98% disease-free survival at 44 months when these
patients had negative axillary lymph nodes, and 67%
when the nodes were found to be involved (4). There
were no local recurrences and distant metastasis in
this study. This, too, is consistent with the results of
others, who have reported a high disease free survival
rate for nonpalpable breast cancer. But, our median
follow-up (27 months) is shorter than the other studies.
We conclude that NLBB is a safe and effective
method of biopsying nonpalpable breast lesions. It continues to be a reliable method of detecting early
breast carcinoma. This procedure should be done in all
patients with mammographically suspicious nonpalpable
breast lesions. In addition, we propose that all nonpalpable lesions be identified and
then evaluated
based on risk of malignancy.
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